News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Celgene Reports Record Non-GAAP Fourth Quarter and Full Year 2010 Operating and Financial Results
January 27, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): This operating momentum, combined with our continued investment in R&D, positions us well for sustained growth in both the near and long term.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Startups
Ollin Emerges From Stealth With $100M To Develop Eye Disease Bispecifics
September 17, 2025
·
2 min read
·
Tristan Manalac
Artificial Intelligence
The Future of Pharma Is Predictive Care Powered by Consumers, AI: PwC
September 17, 2025
·
2 min read
·
Annalee Armstrong
Gene therapy
Doctors Still Prescribing Sarepta’s DMD Gene Therapy After Safety Concerns
September 16, 2025
·
3 min read
·
Annalee Armstrong
Drug pricing
Sanofi Joins Growing Group of Pharmas Pulling Back From UK
September 16, 2025
·
2 min read
·
Tristan Manalac